82_FR_32848 82 FR 32713 - Government-Owned Inventions; Availability for Licensing

82 FR 32713 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 135 (July 17, 2017)

Page Range32713-32714
FR Document2017-14861

The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 82 Issue 135 (Monday, July 17, 2017) 
[Federal Register Volume 82, Number 135 (Monday, July 17, 2017)]
[Notices]
[Pages 32713-32714]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-14861]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Dr. Peter Tung; 240-669-5483; 
peter.tung@nih.gov. Licensing information and copies of the patent 
applications listed below may be obtained by communicating with the 
indicated licensing contact at the Technology Transfer and Intellectual 
Property Office, National Institute of Allergy and Infectious Diseases, 
5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Compounds That Treat Malaria and Prevent Malaria Transmission

Description of Technology

    Malaria is the single leading cause of death, especially among 
children, in the developing world. Malaria is caused by infection with 
parasites of the genus Plasmodium, transmitted by mosquitos. In 
addition to transmission, vital steps in the parasite lifecycle occur 
in the mosquito host. The invention offered for licensing relates to 
therapeutic compounds and related pharmaceutical compositions that can 
be used in the prevention and treatment of malaria infection. More 
specifically, the invention is drawn to compounds that may kill sexual 
and mosquito stage malaria parasites to block transmission. 
Specifically claimed is the antihistamine Ketotifen, which has 
demonstrated activity blocking parasite development in mosquitoes. Also 
claimed are treatments encompassing Ketotifen with other existing 
antimalarial drugs in a combination treatment aimed at multiple stages 
in the malaria life cycle.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

 Prevention and treatment of malaria infections

Competitive Advantages

     Drugs that kill sexual and mosquito stages of the parasite 
are important for preventing and/or slowing the spread of malaria 
infection and ultimately for malaria eradication.
     Primaquine, the only currently available drug shown to 
block transmission, is known to cause serious adverse side effects.

Development Stage

 Pre-Clinical (animal data available)

    Inventors: Xin-zhuan Su and Dipak Raj (NIAID).
    Publications: Eastman R.T. Pattaradilokrat S. Raj D.K. Dixit S. 
Deng B. Miura K. Yuan J. Tanaka T.Q. Johnson R.L. Jiang H. et al. 2013. 
A class

[[Page 32714]]

of tricyclic compounds blocking malaria parasite oocyst development and 
transmission. Antimicrob. Agents Chemother. 57: 425-435.
    Intellectual Property: US Patent # 9,375,424, US divisional patent 
application: 13/392,668, Worldwide patent applications: Canada 2772085, 
Europe 10812670.7, India 1684/DELNP/2012. Priority Application 61/
237,417 filed August 27, 2009. (HHS Reference No. E-283-2009)
    Licensing Contact: Peter Tung, Ph.D.; 240-669-5483; 
peter.tung@nih.gov.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize this technology. For collaboration 
opportunities, please contact Peter Tung; 240-669-5483; 
peter.tung@nih.gov.

    Dated: July 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-14861 Filed 7-14-17; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 135 / Monday, July 17, 2017 / Notices 32713 The prospective exclusive license Dated: July 6, 2017. Office, National Institute of Allergy and territory may be worldwide and the Richard U. Rodriguez, Infectious Diseases, 5601 Fishers Lane, field of use may be limited to the use Associate Director, Technology Transfer Rockville, MD, 20852; tel. 301–496– of Licensed Patent Rights for the Center, National Cancer Institute. 2644. A signed Confidential Disclosure following: ‘‘Development, commercial [FR Doc. 2017–14860 Filed 7–14–17; 8:45 am] Agreement will be required to receive application and use of fulvestrant in BILLING CODE 4140–01–P copies of unpublished patent estrogen receptor positive cancers, in applications. combination with other products and SUPPLEMENTARY INFORMATION: therapies, excluding poxvirus-based DEPARTMENT OF HEALTH AND Technology description follows. vaccines.’’ For avoidance of doubt, the HUMAN SERVICES Compounds That Treat Malaria and field of use specifically excludes the use National Institutes of Health Prevent Malaria Transmission of fulvestrant in combination with poxvirus-based vaccines. National Institute on Drug Abuse; Description of Technology This technology discloses the use of Amended Notice of Meeting Malaria is the single leading cause of fulvestrant, an estrogen receptor Notice is hereby given of a change in death, especially among children, in the antagonist, as an immune modulating the meeting of the National Institute on developing world. Malaria is caused by agent that enhances the effects of Drug Abuse Special Emphasis Panel, infection with parasites of the genus immunotherapy and/or chemotherapy July 27, 2017, 09:00 a.m. to July 27, Plasmodium, transmitted by mosquitos. in cancer cells. Fulvestrant treatment of 2017, 05:00 p.m., National Institutes of In addition to transmission, vital steps mesenchymal-like lung carcinoma cells Health, Neuroscience Center, 6001 in the parasite lifecycle occur in the increases immune-mediated lysis by Executive Boulevard, Rockville, MD mosquito host. The invention offered for reversing epithelial mesenchymal 20852 which was published in the licensing relates to therapeutic Federal Register on June 29, 2017, 82 compounds and related pharmaceutical transition (EMT), potentially repairing 125 FR 2017–13696. compositions that can be used in the defective cell death mechanisms driven This meeting was amended to change prevention and treatment of malaria by EMT, and restoring immune- infection. More specifically, the mediated lysis to chemo-resistant cells. the date from July 27, 2017 to July 25, 2017. The time of the meeting remains invention is drawn to compounds that Overall, treatment of cancer cells with may kill sexual and mosquito stage the same. The meeting is closed to the fulvestrant in combination with malaria parasites to block transmission. public. immunotherapy or chemotherapy agents Specifically claimed is the results in increased cancer cell death. Dated: July 10, 2017. antihistamine Ketotifen, which has Although immunotherapy is leading the Natasha M. Copeland, demonstrated activity blocking parasite charge in cancer treatments, its efficacy Program Analyst, Office of Federal Advisory development in mosquitoes. Also is limited by patient resistance to Committee Policy. claimed are treatments encompassing immunotherapy and/or non- [FR Doc. 2017–14858 Filed 7–14–17; 8:45 am] Ketotifen with other existing responsiveness. Combination therapy BILLING CODE 4140–01–P antimalarial drugs in a combination with fulvestrant that enhances the treatment aimed at multiple stages in therapeutic effects of immunotherapy the malaria life cycle. DEPARTMENT OF HEALTH AND This technology is available for and chemotherapy, is a promising HUMAN SERVICES licensing for commercial development strategy to improve the clinical outcome for patients with resistant or National Institutes of Health in accordance with 35 U.S.C. 209 and 37 unresponsive tumors. CFR part 404, as well as for further Government-Owned Inventions; development and evaluation under a This notice is made in accordance research collaboration. with 35 U.S.C. 209 and 37 CFR part 404. Availability for Licensing The prospective exclusive license will AGENCY: National Institutes of Health, Potential Commercial Applications be royalty bearing, and the prospective HHS. • Prevention and treatment of malaria exclusive license may be granted unless ACTION: Notice. infections within fifteen (15) days from the date of SUMMARY: The invention listed below is Competitive Advantages this published notice, the National Cancer Institute receives written owned by an agency of the U.S. • Drugs that kill sexual and mosquito evidence and argument that establishes Government and is available for stages of the parasite are important for that the grant of the license would not licensing to achieve expeditious preventing and/or slowing the spread of commercialization of results of malaria infection and ultimately for be consistent with the requirements of federally-funded research and malaria eradication. 35 U.S.C. 209 and 37 CFR part 404. development. Foreign patent • Primaquine, the only currently Complete applications for a license in applications are filed on selected available drug shown to block the prospective field of use that are filed inventions to extend market coverage transmission, is known to cause serious in response to this notice will be treated for companies and may also be available adverse side effects. as objections to the grant of the for licensing. asabaliauskas on DSKBBXCHB2PROD with NOTICES contemplated Exclusive Development Stage FOR FURTHER INFORMATION CONTACT: Dr. Commercialization Patent License Peter Tung; 240–669–5483; peter.tung@ • Pre-Clinical (animal data available) Agreement. Comments and objections nih.gov. Licensing information and Inventors: Xin-zhuan Su and Dipak submitted to this notice will not be copies of the patent applications listed Raj (NIAID). made available for public inspection below may be obtained by Publications: Eastman R.T. and, to the extent permitted by law, will communicating with the indicated Pattaradilokrat S. Raj D.K. Dixit S. Deng not be released under the Freedom of licensing contact at the Technology B. Miura K. Yuan J. Tanaka T.Q. Information Act, 5 U.S.C. 552. Transfer and Intellectual Property Johnson R.L. Jiang H. et al. 2013. A class VerDate Sep<11>2014 17:45 Jul 14, 2017 Jkt 241001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\17JYN1.SGM 17JYN1

32714 Federal Register / Vol. 82, No. 135 / Monday, July 17, 2017 / Notices of tricyclic compounds blocking malaria Place: National Institutes of Health, 5601 Agenda: To review and evaluate grant parasite oocyst development and Fishers Lane, Rockville, MD 20892 applications. transmission. Antimicrob. Agents (Telephone Conference Call). Place: National Institutes of Health, 5601 Contact Person: Robert C. Unfer, Ph.D., Fishers Lane, Rockville, MD 20892 Chemother. 57: 425–435. Scientific Review Officer, Scientific Review (Telephone Conference Call). Intellectual Property: US Patent # Program, Division of Extramural Activities, Contact Person: Louis A. Rosenthal, Ph.D., 9,375,424, US divisional patent Room 3F40A, National Institutes of Health, Scientific Review Officer, Immunology application: 13/392,668, Worldwide NIAID, 5601 Fishers Lane, MSC 9834, Review Branch, 5601 Fishers Lane, patent applications: Canada 2772085, Bethesda, MD 20892–9834, (240) 669–5035, Telephone: 240–669–5070, Fax: 301–480– Europe 10812670.7, India 1684/DELNP/ robert.unfer@nih.gov. 2408, rosenthalla@niaid.nih.gov. 2012. Priority Application 61/237,417 (Catalogue of Federal Domestic Assistance Name of Committee: National Institute of filed August 27, 2009. (HHS Reference Program Nos. 93.855, Allergy, Immunology, Allergy and Infectious Diseases Special and Transplantation Research; 93.856, Emphasis Panel; NIAID Clinical Trial No. E–283–2009) Implementation Grant (R01). Microbiology and Infectious Diseases Licensing Contact: Peter Tung, Ph.D.; Research, National Institutes of Health, HHS) Date: August 10, 2017. 240–669–5483; peter.tung@nih.gov. Time: 1:00 p.m. to 2:30 p.m. Dated: July 10, 2017. Agenda: To review and evaluate grant Collaborative Research Opportunity: Natasha M. Copeland, applications. The National Institute of Allergy and Place: National Institutes of Health, 5601 Infectious Diseases is seeking statements Program Analyst, Office of Federal Advisory Committee Policy. Fishers Lane, Rockville, MD 20892 of capability or interest from parties (Telephone Conference Call). interested in collaborative research to [FR Doc. 2017–14856 Filed 7–14–17; 8:45 am] Contact Person: Roberta Binder, Ph.D., further develop, evaluate or BILLING CODE 4140–01–P Scientific Review Officer, Scientific Review commercialize this technology. For Program, Division of Extramural Activities, collaboration opportunities, please Room 3G21A, National Institutes of Health/ contact Peter Tung; 240–669–5483; DEPARTMENT OF HEALTH AND NIAID, 5601 Fishers Lane, MSC 9823, peter.tung@nih.gov. HUMAN SERVICES Bethesda, MD 20892–9823, (240) 669–5050, rbinder@niaid.nih.gov. Dated: July 6, 2017. National Institutes of Health (Catalogue of Federal Domestic Assistance Suzanne Frisbie, Program Nos. 93.855, Allergy, Immunology, Deputy Director, Technology Transfer and National Institute of Allergy and and Transplantation Research; 93.856, Intellectual Property Office, National Institute Infectious Diseases; Notice of Closed Microbiology and Infectious Diseases of Allergy and Infectious Diseases. Meetings Research, National Institutes of Health, HHS) [FR Doc. 2017–14861 Filed 7–14–17; 8:45 am] Dated: July 10, 2017. Pursuant to section 10(d) of the BILLING CODE 4140–01–P Federal Advisory Committee Act, as Natasha M. Copeland, amended (5 U.S.C. App.), notice is Program Analyst, Office of Federal Advisory hereby given of the following meetings. Committee Policy. DEPARTMENT OF HEALTH AND [FR Doc. 2017–14855 Filed 7–14–17; 8:45 am] HUMAN SERVICES The meetings will be closed to the public in accordance with the BILLING CODE 4140–01–P National Institutes of Health provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., National Institute of Allergy and as amended. The grant applications and DEPARTMENT OF HEALTH AND Infectious Diseases; Notice of Closed the discussions could disclose HUMAN SERVICES Meeting confidential trade secrets or commercial National Institutes of Health property such as patentable material, Pursuant to section 10(d) of the and personal information concerning Center for Scientific Review; Notice of Federal Advisory Committee Act, as individuals associated with the grant Closed Meetings amended (5 U.S.C. App.), notice is applications, the disclosure of which hereby given of the following meeting. would constitute a clearly unwarranted Pursuant to section 10(d) of the The meeting will be closed to the invasion of personal privacy. Federal Advisory Committee Act, as public in accordance with the amended (5 U.S.C. App.), notice is Name of Committee: National Institute of hereby given of the following meetings. provisions set forth in sections Allergy and Infectious Diseases Special 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., The meetings will be closed to the Emphasis Panel; NIAID Clinical Trial as amended. The grant applications and Planning Grant (R34). public in accordance with the the discussions could disclose Date: August 8, 2017. provisions set forth in sections confidential trade secrets or commercial Time: 1:15 p.m. to 2:30 p.m. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., property such as patentable material, Agenda: To review and evaluate grant as amended. The grant applications and and personal information concerning applications. the discussions could disclose individuals associated with the grant Place: National Institutes of Health, 5601 confidential trade secrets or commercial Fishers Lane, Rockville, MD 20892 property such as patentable material, applications, the disclosure of which (Telephone Conference Call). would constitute a clearly unwarranted and personal information concerning Contact Person: Louis A. Rosenthal, Ph.D., individuals associated with the grant invasion of personal privacy. Scientific Review Officer, Immunology asabaliauskas on DSKBBXCHB2PROD with NOTICES Review Branch, 5601 Fishers Lane, applications, the disclosure of which Name of Committee: Microbiology, would constitute a clearly unwarranted Infectious Diseases and AIDS Initial Review Telephone: 240–669–5070, Fax: 301–480– Group; Acquired Immunodeficiency 2408, rosenthalla@niaid.nih.gov. invasion of personal privacy. Syndrome Research Review Committee Name of Committee: National Institute of Name of Committee: Center for Scientific AIDS. Allergy and Infectious Diseases Special Review Special Emphasis Panel; Member Date: August 10–11, 2017. Emphasis Panel; NIAID Clinical Trial Conflict: International and Cooperative Time: 8:00 a.m. to 6:00 p.m. Planning Grant (R34). Projects 1. Agenda: To review and evaluate grant Date: August 8, 2017. Date: July 21, 2017. applications. Time: 12:00 p.m. to 1:15 p.m. Time: 10:30 a.m. to 12:00 p.m. VerDate Sep<11>2014 17:45 Jul 14, 2017 Jkt 241001 PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 E:\FR\FM\17JYN1.SGM 17JYN1


Document Created: 2017-07-15 03:45:41
Document Modified: 2017-07-15 03:45:41
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactDr. Peter Tung; 240-669-5483; [email protected] Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation82 FR 32713 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR